ACME LaboratoriesDHA:ACMELAB +0.61%82 Quick Ratio is 0.65 as of Mar. 2026, which is 2% above its 10-year median of 0.64. GuruFocus rates DHA:ACMELAB with a GF Score™ of 82/100 and a GF Value™ of BDT124.98 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 995 Drug Manufacturers companies, ACME Laboratories ranks worse than 83.02% on this metric.
ACME Laboratories has a quick ratio of 0.65. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for ACME Laboratories's Quick Ratio or its related term are showing as below:
DHA:ACMELAB'
s Quick Ratio Range Over the Past 10 Years
Min: 0.53 Med: 0.64 Max: 0.99
Current: 0.65
During the past 9 years, ACME Laboratories's highest Quick Ratio was 0.99. The lowest was 0.53. And the median was 0.64.
DHA:ACMELAB's Quick Ratio is ranked worse than 83.02% of 995
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs DHA:ACMELAB: 0.65
ACME Laboratories (DHA:ACMELAB) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
ACME Laboratories Quick Ratio Related Terms
ACME Laboratories Quick Ratio Historical Data
* Premium members only.
The historical data trend for ACME Laboratories's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ACMELAB vs ZTS, UTHR, VTRS: Quick Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ACME Laboratories's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACME Laboratories Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ACME Laboratories's Quick Ratio distribution charts can be found below:
* The bar in red indicates where ACME Laboratories's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
ACME Laboratories's Quick Ratio for the fiscal year that ended in Jun. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACME Laboratories (DHA:ACMELAB) has a Quick Ratio of 0.65 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on ACME Laboratories and its competitors. This is near median its historical median of 0.64. Over the past decade, ACME Laboratories' Quick Ratio has ranged from 0.53 to 0.99. According to the industry distribution chart, ACME Laboratories ranks #826 out of 995 companies in the Drug Manufacturers industry, placing it in the top 83%.
Is ACME Laboratories' Quick Ratio too high?
ACME Laboratories' current Quick Ratio of 0.65 is near median its 10-year median of 0.64. Over the past 10 years, this metric has ranged from a low of 0.53 to a high of 0.99. The Drug Manufacturers industry median Quick Ratio is 1.45. ACME Laboratories' value of 0.65 is 55.2% below this industry median. Based on the distribution chart, ACME Laboratories ranks #826 out of 995 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, ACME Laboratories has a GF Score™ of 82/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' Quick Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ACME Laboratories ranks #826 out of 995 companies for Quick Ratio. This places ACME Laboratories in the lower half of its industry. The industry median Quick Ratio is 1.45. ACME Laboratories' value of 0.65 is 55.2% below this benchmark. Historically, ACME Laboratories' own Quick Ratio has ranged from 0.53 to 0.99 over the past decade. While the company's 10-year median is 0.64 vs. the industry median of 1.45, ACME Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACME Laboratories's current Quick Ratio of 0.65 is 55.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on ACME Laboratories and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACME Laboratories's current Quick Ratio is 0.65, which is near median its own 10-year median of 0.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT124.98, compared to a current price of BDT82.40 — trading 34.1% below its estimated fair value. The current Quick Ratio is 0.65, which is near median its 10-year median of 0.64 and 55.2% below the Drug Manufacturers industry median of 1.45. ACME Laboratories' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current Quick Ratio is 0.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?
Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued.
The current stock price of BDT82.40 is trading 34.1% below its estimated GF Value™ of BDT124.98.
GuruFocus considers ACME Laboratories to be Possible Value Trap.
Key valuation signals for DHA:ACMELAB:
Quick Ratio: 0.65 (near median its 10-year median of 0.64)
GF Value™: BDT124.98 vs. price of BDT82.40 (34.1% below fair value)
Industry Position: 55.2% below the Drug Manufacturers median (#826 of 995)
No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
82GF Score
Get the complete analysis for DHA:ACMELAB
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ACMELAB has been successfully added to your 
